AP402

AP402 is a bispecific antibody developed for the treatment of HER2-positive locally advanced or metastatic solid tumors, including breast cancer. It is currently being evaluated in a Phase 1/2, multi-regional, multi-center, open-label clinical trial to assess its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity. The drug is administered via intravenous infusion every two weeks in both dose escalation and dose expansion phases. The primary developer of AP402 is AP Biosciences. Tasly Pharmaceutical Group also appears as an active organization involved with the drug's development. Mechanism of action has not been publicly disclosed as of April 2025; only that it is a bispecific antibody targeting HER2-positive cancers.